JENNIFER WARGO to Adenocarcinoma
This is a "connection" page, showing publications JENNIFER WARGO has written about Adenocarcinoma.
Connection Strength
0.524
-
From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer. Cell Rep Med. 2023 05 16; 4(5):101039.
Score: 0.238
-
The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov. 2022 11 02; 12(11):2626-2645.
Score: 0.057
-
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097.
Score: 0.040
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.039
-
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
Score: 0.038
-
Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013 Apr; 257(4):731-6.
Score: 0.029
-
Targeting the MAGE A3 antigen in pancreatic cancer. Surgery. 2012 Sep; 152(3 Suppl 1):S13-8.
Score: 0.028
-
Superior prognostic importance of perineural invasion vs. lymph node involvement after curative resection of duodenal adenocarcinoma. J Gastrointest Surg. 2012 Jan; 16(1):113-20; discussion 120.
Score: 0.027
-
Surgical approach to pancreatic exocrine neoplasms. Minerva Chir. 2005 Dec; 60(6):445-68.
Score: 0.018
-
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697.
Score: 0.011